These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32040670)

  • 1. Serum tenascin-C is independently associated with increased major adverse cardiovascular events and death in individuals with type 2 diabetes: a French prospective cohort.
    Gellen B; Thorin-Trescases N; Thorin E; Gand E; Sosner P; Brishoual S; Rigalleau V; Montaigne D; Javaugue V; Pucheu Y; Gatault P; Piguel X; Hadjadj S; Saulnier PJ;
    Diabetologia; 2020 May; 63(5):915-923. PubMed ID: 32040670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ANGPTL2 is associated with an increased risk of cardiovascular events and death in diabetic patients.
    Gellen B; Thorin-Trescases N; Sosner P; Gand E; Saulnier PJ; Ragot S; Fraty M; Laugier S; Ducrocq G; Montaigne D; Llaty P; Rigalleau V; Zaoui P; Halimi JM; Roussel R; Thorin E; Hadjadj S
    Diabetologia; 2016 Nov; 59(11):2321-2330. PubMed ID: 27491833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating Concentrations of Redox Biomarkers Do Not Improve the Prediction of Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus.
    Cournot M; Burillo E; Saulnier PJ; Planesse C; Gand E; Rehman M; Ragot S; Rondeau P; Catan A; Gonthier MP; Feigerlova E; Meilhac O; Hadjadj S
    J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29478972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-sensitivity troponin I and B-type natriuretic peptide biomarkers for prediction of cardiovascular events in patients with coronary artery disease with and without diabetes mellitus.
    Wong YK; Cheung CYY; Tang CS; Hai JSH; Lee CH; Lau KK; Au KW; Cheung BMY; Sham PC; Xu A; Lam KSL; Tse HF
    Cardiovasc Diabetol; 2019 Dec; 18(1):171. PubMed ID: 31847896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between serum HDL-cholesterol, cardiovascular disease and mortality in community-based people with type 2 diabetes: the Fremantle Diabetes Study phase 2.
    Davis TME; Chubb SAP; Davis WA
    Cardiovasc Diabetol; 2024 Oct; 23(1):362. PubMed ID: 39402659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction.
    Sato A; Aonuma K; Imanaka-Yoshida K; Yoshida T; Isobe M; Kawase D; Kinoshita N; Yazaki Y; Hiroe M
    J Am Coll Cardiol; 2006 Jun; 47(11):2319-25. PubMed ID: 16750702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
    Ferdinand KC; Botros FT; Atisso CM; Sager PT
    Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-6 and activin A are independently associated with cardiovascular events and mortality in type 2 diabetes: the prospective Asker and Bærum Cardiovascular Diabetes (ABCD) cohort study.
    Ofstad AP; Gullestad L; Orvik E; Aakhus S; Endresen K; Ueland T; Aukrust P; Fagerland MW; Birkeland KI; Johansen OE
    Cardiovasc Diabetol; 2013 Aug; 12():126. PubMed ID: 23987834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of serum tenascin-C levels on long-term outcome after acute myocardial infarction.
    Sato A; Hiroe M; Akiyama D; Hikita H; Nozato T; Hoshi T; Kimura T; Wang Z; Sakai S; Imanaka-Yoshida K; Yoshida T; Aonuma K
    J Card Fail; 2012 Jun; 18(6):480-6. PubMed ID: 22633306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic importance of visit-to-visit blood pressure variability for micro- and macrovascular outcomes in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study.
    Cardoso CRL; Leite NC; Salles GF
    Cardiovasc Diabetol; 2020 May; 19(1):50. PubMed ID: 32359350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALTITUDE trial.
    Seferovic JP; Pfeffer MA; Claggett B; Desai AS; de Zeeuw D; Haffner SM; McMurray JJV; Parving HH; Solomon SD; Chaturvedi N
    Diabetologia; 2018 Mar; 61(3):581-588. PubMed ID: 29098323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory Biomarkers to Predict Major Adverse Cardiovascular Events in Patients with Carotid Artery Stenosis.
    Li B; Shaikh F; Zamzam A; Abdin R; Qadura M
    Medicina (Kaunas); 2024 Jun; 60(6):. PubMed ID: 38929614
    [No Abstract]   [Full Text] [Related]  

  • 13. High circulating levels of large splice variants of tenascin-C is associated with mortality and cardiovascular disease in chronic kidney disease patients.
    Liabeuf S; Barreto DV; Kretschmer A; Barreto FC; Renard C; Andrejak M; Choukroun G; Massy Z
    Atherosclerosis; 2011 Mar; 215(1):116-24. PubMed ID: 21183183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galectin-3 and risk of cardiovascular events and all-cause mortality in type 2 diabetes.
    Tan KCB; Cheung CL; Lee ACH; Lam JKY; Wong Y; Shiu SWM
    Diabetes Metab Res Rev; 2019 Feb; 35(2):e3093. PubMed ID: 30378236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of the ankle-brachial index on the development of micro- and macrovascular complications in individuals with type 2 diabetes: the Rio de Janeiro Type 2 Diabetes Cohort Study.
    Cardoso CRL; Melo JV; Salles GC; Leite NC; Salles GF
    Diabetologia; 2018 Nov; 61(11):2266-2276. PubMed ID: 30112690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic Changes in Renal Function Are Associated With Major Cardiovascular Events in Patients With Type 2 Diabetes.
    Ragot S; Saulnier PJ; Velho G; Gand E; de Hauteclocque A; Slaoui Y; Potier L; Sosner P; Halimi JM; Zaoui P; Rigalleau V; Fumeron F; Roussel R; Marre M; Hadjadj S;
    Diabetes Care; 2016 Jul; 39(7):1259-66. PubMed ID: 27222502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma Trimethylamine N-Oxide and Risk of Cardiovascular Events in Patients With Type 2 Diabetes.
    Croyal M; Saulnier PJ; Aguesse A; Gand E; Ragot S; Roussel R; Halimi JM; Ducrocq G; Cariou B; Montaigne D; Wargny M; Krempf M; Hadjadj S
    J Clin Endocrinol Metab; 2020 Jul; 105(7):. PubMed ID: 32301490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes.
    El Khoury P; Roussel R; Fumeron F; Abou-Khalil Y; Velho G; Mohammedi K; Jacob MP; Steg PG; Potier L; Ghaleb Y; Elbitar S; Ragot S; Andreata F; Caligiuri G; Hadjadj S; Boileau C; Marre M; Abifadel M; Varret M; Hansel B
    Diabetes Obes Metab; 2018 Apr; 20(4):943-953. PubMed ID: 29205760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toe-brachial index as a predictor of cardiovascular disease and all-cause mortality in people with type 2 diabetes and microalbuminuria.
    Zobel EH; von Scholten BJ; Reinhard H; Persson F; Hansen TW; Parving HH; Jacobsen PK; Rossing P
    Diabetologia; 2017 Oct; 60(10):1883-1891. PubMed ID: 28681124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of radial pulse spectrum on the risk of major adverse cardiovascular events in patients with type 2 diabetes.
    Chang CW; Liao KM; Chang YT; Wang SH; Chen YC; Wang GC
    J Diabetes Complications; 2019 Feb; 33(2):160-164. PubMed ID: 30381150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.